Search Results

You are looking at 61 - 70 of 298 items for :

Clear All
Full access

Manish A. Shah and David P. Kelsen

. Targeted Therapy for Gastric Cancer Her2-Positive Gastric Cancer Her2 is a member of the epidermal growth factor receptor family of tyrosine kinase receptors responsible for cell growth, survival, adhesion, migration, and differentiation. Her2-driven

Full access

Heather Katz, Hassaan Jafri, Emilia Cindy Leigh, Layana Biglow, Madhulika Urella and Maria Tria Tirona

performed analyzing 98 charts of patients with stage I–III HER2-positive breast cancer who were seen at the Edwards Comprehensive Cancer Center (ECCC) in Huntington, WV from January 1, 2012–December 30, 2017. Patients who received trastuzumab at ECCC (59

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla and Arun S. Singh

estrogen receptor (ER)–positive and HER2 /neu-negative. She also had ductal carcinoma in situ (DCIS) in her contralateral left breast. After bilateral mastectomies, she received adjuvant chemotherapy with doxorubicin and cyclophosphamide (AC) followed by

Full access

Natasha Hunter, Sarah Croessmann, Karen Cravero, Daniel Shinn, Paula J. Hurley and Ben Ho Park

clinical utility of cfDNA in patients with early-stage, HER2-positive and triple-negative breast cancer in a large-scale, multi-institutional prospective study ( ClinicalTrials.gov identifier: NCT02743910). In this study, we assessed cfDNA from a patient

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin and Craig A. Bunnell

delays in adjuvant chemotherapy initiation greater than 49 to 90 days after surgery may be associated with inferior outcomes, particularly among patients with triple-negative breast cancer (TNBC), HER2-positive subtypes, and higher-stage tumors. 7 – 12 A

Full access

Lee S. Schwartzberg

commercially available assays at the NCCN 22nd Annual Conference. Using GEP to Tailor Treatment For patients with hormone receptor–positive, HER2-negative disease—some 70% of patients with early-stage breast cancer—multigene assays can aid in decision

Full access

Titilayo O. Adegboyega, Jeffrey Landercasper, Jared H. Linebarger, Jeanne M. Johnson, Jeremiah J. Andersen, Leah L. Dietrich, Collin D. Driscoll, Meghana Raghavendra, Anusha R. Madadi, Mohammed Al-Hamadani, Choua A. Vang, Kristen A. Marcou, Jane Hudak and Ronald S. Go

. The following factors were analyzed for their influence on compliance with NCCN Guidelines: age, Charlson comorbidity index 16 (CCI), estrogen receptor (ER)/progesterone receptor (PR)/HER2 status by immunohistochemistry and fluorescence in situ

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar and E. Aubrey Thompson

right axillary lymphadenopathy. A punch biopsy of the tumor revealed grade 3 infiltrating ductal carcinoma, estrogen receptor (ER)–positive by immunohistochemistry (IHC) at 76% to 100%, progesterone receptor (PR) focally positive at 10%, HER2

Full access

Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford and Melinda L. Telli

have a 2.7-cm moderately differentiated invasive ductal carcinoma that was estrogen receptor–positive/progesterone receptor–positive/HER2-positive (ER+/PR+/HER2+) on immunohistochemistry. Lymph node dissection was negative in 0 of 23 nodes. Surgical

Full access

Megan C. Roberts, Allison W. Kurian and Valentina I. Petkov

Background The Oncotype DX Breast Recurrence Score (RS) test is a 21-gene expression assay that became commercially available for clinical use in 2004. In patients with early-stage, hormone receptor−positive (HR+), HER2-negative breast cancer, RS